ResMed's fourth-quarter fiscal 2025 underlying EBIT grew 7% on the third, driven by increased product demand and gross margin expanding 150 basis points to 61% on component cost improvements and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback